Gastric acid secretion inhibiting composition
US7785626B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2003 |
| Grant date | Aug 31, 2010 |
| Priority date | — |
| Expiry date | Dec 8, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/1676
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.